Search Results - Sewak, N.P.S

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe: How Do Payers and Key Stakeholders Perceive Them?

    Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe: How Do Payers and Key Stakeholders Perceive Them? by Sewak, N.P.S, Jones, C

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    The Hybrid Purchaser-Provider Split in England: Should Europe Follow Suit?

    The Hybrid Purchaser-Provider Split in England: Should Europe Follow Suit? by Sewak, N.P.S, Devienne, E, Karia, R

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    The Introduction Of Biosimilar Monoclonal Antibodies Into Developed Markets: What Are Payers Concerned About?

    The Introduction Of Biosimilar Monoclonal Antibodies Into Developed Markets: What Are Payers Concerned About? by Sewak, N.P.S, Whitcher, C, Neophytou, I

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    PMS86 - Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe: How Do Payers and Key Stakeholders Perceive Them?

    PMS86 - Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe: How Do Payers and Key Stakeholders Perceive Them? by Sewak, N.P.S., Jones, C.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    PHP55 - The Hybrid Purchaser-Provider Split in England: Should Europe Follow Suit?

    PHP55 - The Hybrid Purchaser-Provider Split in England: Should Europe Follow Suit? by Sewak, N.P.S., Devienne, E., Karia, R.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PMS60 - The Introduction Of Biosimilar Monoclonal Antibodies Into Developed Markets: What Are Payers Concerned About?

    PMS60 - The Introduction Of Biosimilar Monoclonal Antibodies Into Developed Markets: What Are Payers Concerned About? by Sewak, N.P.S., Whitcher, C., Neophytou, I.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: